Jane Street
ACRS icon

Jane Street’s Aclaris Therapeutics ACRS Stock Holding History

Jane Street’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,216
Closed -$91.8K – 11416
2025
Q4 		$81.9K Sell
27,216
-45,897
-63% -$116K ﹤0.01% 10293
2025
Q3 		$139K Buy
+73,113
New +$127K ﹤0.01% 9940
2025
Q2 		– Sell
-390,282
Closed -$597K – 9500
2025
Q1 		$597K Sell
390,282
-155,282
-28% -$331K ﹤0.01% 6539
2024
Q4 		$1.35M Buy
545,564
+462,837
+559% +$1.15M ﹤0.01% 4838
2024
Q3 		$95.1K Sell
82,727
-252,282
-75% -$309K ﹤0.01% 9008
2024
Q2 		$369K Buy
335,009
+3,269
+1% +$3.84K ﹤0.01% 7482
2024
Q1 		$411K Buy
331,740
+72,356
+28% +$86.3K ﹤0.01% 7042
2023
Q4 		$272K Buy
259,384
+95,324
+58% +$291K ﹤0.01% 7746
2023
Q3 		$1.12M Buy
164,060
+13,025
+9% +$111K ﹤0.01% 5006
2023
Q2 		$1.57M Sell
151,035
-26,426
-15% -$239K ﹤0.01% 4527
2023
Q1 		$1.44M Buy
+177,461
New +$2.25M ﹤0.01% 4372
2022
Q1 		– Sell
-31,228
Closed -$426K – 10182
2021
Q4 		$454K Sell
31,228
-9,492
-23% -$144K ﹤0.01% 7444
2021
Q3 		$733K Buy
+40,720
New +$653K ﹤0.01% 6546
2021
Q2 		– Sell
-24,302
Closed -$552K – 9687
2021
Q1 		$612K Buy
24,302
+11,601
+91% +$227K ﹤0.01% 6432
2020
Q4 		$82K Sell
12,701
-16,771
-57% -$70.7K ﹤0.01% 7248
2020
Q3 		$76K Sell
29,472
-172,711
-85% -$386K ﹤0.01% 6820
2020
Q2 		$328K Buy
+202,183
New +$271K ﹤0.01% 5704
2019
Q4 		– Sell
-14,476
Closed -$16K – 4985
2019
Q3 		$16K Sell
14,476
-17,071
-54% -$24.2K ﹤0.01% 4960
2019
Q2 		$69K Buy
+31,547
New +$172K ﹤0.01% 4914

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jane Street's ACRS Position: Q1 2026 in Review

Jane Street sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 27,216 shares — an estimated $91.8K sold.

Jane Street first reported a position in ACRS in Q2 2019 and held it in 19 quarters. The position peaked at $1.57M in Q2 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Jane Street reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 27,216 Aclaris Therapeutics shares in Q1 2026, an estimated $91.8K.
  • Jane Street first reported a position in Aclaris Therapeutics in Q2 2019 and held it in 19 quarters.
  • Jane Street's Aclaris Therapeutics position peaked at $1.57M in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.